PD15-07 IMPACT OF BONE-TARGETED THERAPIES IN PATIENTS WITH CHEMOTHERAPY-NAIVE METASTATIC CASTRATION-RESISTANT PROSTATE CANCER ON ENZALUTAMIDE: A POST HOC ANALYSIS OF PREVAIL

Post Hoc Analysis ◽

Castration Resistant ◽

Impact of Bone-targeted Therapies in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer Patients Treated with Abiraterone Acetate: Post Hoc Analysis of Study COU-AA-302

European Urology ◽

10.1016/j.eururo.2015.04.032 ◽

2015 ◽

Vol 68 (4) ◽

pp. 570-577 ◽

Cited By ~ 33

Author(s):

Fred Saad ◽

Neal Shore ◽

Hendrik Van Poppel ◽

Dana E. Rathkopf ◽

Matthew R. Smith ◽

...

Keyword(s):

Prostate Cancer ◽

Cancer Patients ◽

Targeted Therapies ◽

Abiraterone Acetate ◽

Post Hoc Analysis ◽

Castration Resistant ◽

The PREVAIL trial of enzalutamide in men with chemotherapy-naïve, metastatic castration-resistant prostate cancer: Post hoc analysis of Korean patients

Investigative and Clinical Urology ◽

10.4111/icu.2016.57.3.174 ◽

2016 ◽

Vol 57 (3) ◽

pp. 174 ◽

Cited By ~ 11

Author(s):

Choung-Soo Kim ◽

Ad Theeuwes ◽

Dong Deuk Kwon ◽

Young Deuk Choi ◽

Byung Ha Chung ◽

...

Keyword(s):

Prostate Cancer ◽

Post Hoc Analysis ◽

Korean Patients ◽

Castration Resistant ◽

Post hoc analysis of the effect of baseline characteristics on treatment duration in patients with metastatic castration-resistant prostate cancer (mCRPC) receiving cabazitaxel in the compassionate use (CUP)/expanded access programs (EAP) and CAPRISTANA registry

Annals of Oncology ◽

10.1093/annonc/mdy284.027 ◽

2018 ◽

Vol 29 ◽

pp. viii284-viii285

Author(s):

Z. Malik ◽

A. Pichler ◽

G. Di Lorenzo ◽

U. De Giorgi ◽

S. Hitier ◽

...

Keyword(s):

Prostate Cancer ◽

Treatment Duration ◽

Compassionate Use ◽

Post Hoc Analysis ◽

Expanded Access ◽

Castration Resistant ◽

Baseline Characteristics ◽

Post Hoc ◽

Access Programs

668 Response to taxane chemotherapy as first subsequent therapy after abiraterone acetate in patients with metastatic castration-resistant prostate cancer (mCRPC): Post hoc analysis of COU-AA-302

European Urology Supplements ◽

10.1016/s1569-9056(15)60661-3 ◽

2015 ◽

Vol 14 (2) ◽

pp. e668-e668a ◽

Cited By ~ 1

Author(s):

F. Saad ◽

J.S. De Bono ◽

M.R. Smith ◽

D.E. Rathkopf ◽

P.F.A. Mulders ◽

...

Keyword(s):

Prostate Cancer ◽

Abiraterone Acetate ◽

Post Hoc Analysis ◽

Castration Resistant ◽

Taxane Chemotherapy ◽

Association of local progression with deterioration of urinary symptoms and occurrence of genitourinary adverse events (AEs) in nonmetastatic Castration-Resistant Prostate Cancer (nmCRPC): Post hoc analysis of PROSPER

European Urology ◽

10.1016/s0302-2838(21)01596-7 ◽

2021 ◽

Vol 79 ◽

pp. S1738-S1739

Author(s):

M-O. Grimm ◽

M. Hussain ◽

A. Stenzl ◽

T. Todenhöfer ◽

G.P. Haas ◽

...

Keyword(s):

Prostate Cancer ◽

Adverse Events ◽

Urinary Symptoms ◽

Post Hoc Analysis ◽

Castration Resistant ◽

Local Progression ◽

Subsequent Chemotherapy and Treatment Patterns After Abiraterone Acetate in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302

European Urology ◽

10.1016/j.eururo.2016.06.033 ◽

2017 ◽

Vol 71 (4) ◽

pp. 656-664 ◽

Cited By ~ 34

Author(s):

Johann S. de Bono ◽

Matthew R. Smith ◽

Fred Saad ◽

Dana E. Rathkopf ◽

Peter F.A. Mulders ◽

...

Keyword(s):

Prostate Cancer ◽

Abiraterone Acetate ◽

Treatment Patterns ◽

Post Hoc Analysis ◽

Castration Resistant ◽

Radiographic progression with nonrising PSA in metastatic castration-resistant prostate cancer: post hoc analysis of PREVAIL

Prostate Cancer and Prostatic Diseases ◽

10.1038/pcan.2016.71 ◽

2017 ◽

Vol 20 (2) ◽

pp. 221-227 ◽

Cited By ~ 26

Author(s):

A H Bryce ◽

J J Alumkal ◽

A Armstrong ◽

C S Higano ◽

P Iversen ◽

...

Keyword(s):

Prostate Cancer ◽

Radiographic Progression ◽

Post Hoc Analysis ◽

Castration Resistant ◽

Changes in plasma biomarkers following treatment with cabozantinib in metastatic castration-resistant prostate cancer: a post hoc analysis of an extension cohort of a phase II trial

Journal of Translational Medicine ◽

10.1186/s12967-015-0747-y ◽

2016 ◽

Vol 14 (1) ◽

Cited By ~ 8

Author(s):

Raya Leibowitz-Amit ◽

Melania Pintilie ◽

Leila Khoja ◽

Arun A. Azad ◽

Raanan Berger ◽

...

Keyword(s):

Prostate Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Plasma Biomarkers ◽

Post Hoc Analysis ◽

Castration Resistant ◽

Enzalutamide in Japanese patients with chemotherapy‐naïve, metastatic castration‐resistant prostate cancer: A post‐hoc analysis of the placebo‐controlled PREVAIL trial

International Journal of Urology ◽

10.1111/iju.13072 ◽

2016 ◽

Vol 23 (5) ◽

pp. 395-403 ◽

Cited By ~ 12

Author(s):

Go Kimura ◽

Junji Yonese ◽

Takashi Fukagai ◽

Tomomi Kamba ◽

Kazuo Nishimura ◽

...

Keyword(s):

Prostate Cancer ◽

Japanese Patients ◽

Post Hoc Analysis ◽

Castration Resistant ◽

Stereotactic body radiotherapy to lymph nodes in oligoprogressive castration-resistant prostate cancer patients: a post hoc analysis from two phase I clinical trials

Clinical & Experimental Metastasis ◽

10.1007/s10585-021-10126-7 ◽

2021 ◽

Author(s):

D. Pezzulla ◽

G. Macchia ◽

S. Cilla ◽

M. Buwenge ◽

M. Ferro ◽

...

Keyword(s):

Prostate Cancer ◽

Clinical Trials ◽

Phase I ◽

Cancer Patients ◽

Phase I Clinical Trials ◽

Two Phase ◽

Post Hoc Analysis ◽

Castration Resistant ◽